EC145: A novel targeted agent for adenocarcinoma of the lung

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 755-761

  Pribble, Pamela ^a   Edelman, Martin J ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Desacetylvinblastine monohydrazide; EC120; EC145; Folic acid receptor; Vinca alkaloid conjugate

Indexed keywords

EC 145; EC 20; FOLATE RECEPTOR; UNCLASSIFIED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CONSTIPATION; DIAGNOSTIC IMAGING; DRUG MECHANISM; DRUG TARGETING; HUMAN; ILEUS; LUNG ADENOCARCINOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; LUNG NEOPLASMS; VINCA ALKALOIDS;

EID: 84859727702     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.671294     Document Type: Review

References (40)

1. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31 (Pubitemid 30078543)
2. Wozniak AJ, Crowley JJ, Balcerzak S, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a cooperative group study. J Clin Oncol 1992;10:1066-73
3. Sandler A, Nemunatis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced and metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122-30 (Pubitemid 30036345)
4. Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
6. Edelman MJ, Watson D, Xiaofei W, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-55 (Pubitemid 351398075)
7. Sign Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer pro-drug and conjugate design. Curr Med Chem 2008;15:1802-26
8. Minko T, Dharap SS, Pakunlu RI. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004;5:389-406 (Pubitemid 38559349)
9. Janne PA, Wang X, Socinski MA, et al. Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406. World Conference on Lung Cancer; Amsterdam; 2011
10. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
11. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29
12. Parker N, Turk MJ, Wertrick E, et al. Folate receptor expression in carcinomas and normal tissues determined in a quantitative radioligand binding assay. Anal Biochem 2005;338:284-94
13. Weitman SD, Frazier KM, Kamen BA. The Folate receptor in central nervous system malignancies of childhood. J Neurooncol 1994;21:107-12 (Pubitemid 24313772)
14. Toffili G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8 (Pubitemid 27234510)
15. Antony AC. Folate receptors. Annu Rev Nutr 1996;16:501-21 (Pubitemid 26286863)
16. Kaen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 1986;83:5983-7 (Pubitemid 16000638)
17. Keating MJ, Smith TL, McCredie KB, et al. A four year experience with anthracycline, cytosine, arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 1981;47:2779-88 (Pubitemid 11073372)
18. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard, and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004 (Pubitemid 20200187)
19. Kushner BH, Kramer K, Modak S, et al. High-dose cychlophosphamide- irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer 2011;47:84-9
20. Kalapurakal JA, Green DM, Haase G, et al. Outcomes of children with favorable histology Wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and-5. Int J Radiat Oncol Biol Phys 2010;77:554-8
21. Harb WA, Conley BA, LoRusso P, et al. A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer (2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition)). J Clin Oncol 2010;28(15 Suppl):3088
22. Leamon CP, Parker MA, Vlahov IR. Synthesis and biological evaluation of EC20: a new folate derived 99mtc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-10 (Pubitemid 35420011)
23. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62
24. Leamon CP, Reddy JA. Folate targeted chemotherapy. Adv Drug Deliv Rev 2004;56(8):1127-41
25. Zhao XB, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5:309-19 (Pubitemid 351454380)
26. Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010;624:249-65.
27. Vlahov IR, Santhapuram HK, Kleindl PJ, et al. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006;16:5093-6. (Pubitemid 44247701)
28. Yang J, Chen K, Chen JX, et al. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 2006;103:13872-7 (Pubitemid 44414000)
29. Paulos CM, Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor medicated drug delivery. Mol Pharmacol 2004;66:1406-14 (Pubitemid 39564767)
30. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42 (Pubitemid 46815093)
31. Sausville W, LoRusso P, Quinn M, et al. A phase 1 study of EC145 administered weeks 1 and 3 of a 4 week cycle in patients with refractory solid tumors (ASCO Annual Meeting Proceedings (Post-Meeting Edition)). J Clin Oncol 2007;25:2577
32. Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49:1467-76.
33. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007;121:1585-92. (Pubitemid 47328719)
34. Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 2006;17:1226-32. (Pubitemid 44455331)
35. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. Cancer Res 2007;67:4434-42 (Pubitemid 46815093)
36. Naumann RW, Symanowski JT, Ghamande SA, et al. Precedent: a randomized phase II trial comparing EC145 and pegylated lisosomal doxyrubicin (PLD) versus PLD alone, in subjects with platinum-resistant ovarian cancer. Am Soc Clin Oncol Ann Meet 2010;28:5012
37. Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) Phase III Clinical trial. Endocyte. ClinicalTrials.gov. 2011.
38. Reddy JA, Xu LC, Parker N, et al. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45(5):857-66 (Pubitemid 47618567)
39. Naumann RW, Coleman RL, Burger RA, et al. Precedent: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2011;29(Suppl):abstract 5045
40. Garon EB, Harb WA, Pal SE, et al. ECFV-03: a phase II study of EC145 (folate-receptor targeted therapy) in patients with advanced lung cancer. J Thorac Oncol 2009;4:452